U.S. Markets closed

GlaxoSmithKline plc (GSK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
35.09-0.26 (-0.74%)
At close: 4:00PM EDT

35.18 +0.09 (0.26%)
After hours: 5:26PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close35.35
Open35.22
Bid0.00 x 3000
Ask0.00 x 1800
Day's Range34.89 - 35.26
52 Week Range31.43 - 48.25
Volume6,891,136
Avg. Volume3,234,178
Market Cap87.31B
Beta (5Y Monthly)0.34
PE Ratio (TTM)35.37
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.89 (5.34%)
Ex-Dividend DateMay 14, 2020
1y Target EstN/A
  • Barrons.com

    Glaxo Vaccines Target Another Viral Threat

    GlaxoSmithKline is testing two vaccines that could protect newborns and people over age 60 from RSV, a virus that has defied vaccine developers for years.

  • GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
    Zacks

    GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

    GlaxoSmithKline (GSK) closed at $35.35 in the latest trading session, marking a -1.91% move from the prior day.

  • GSK to launch late-stage testing of syncytial virus vaccine
    Reuters

    GSK to launch late-stage testing of syncytial virus vaccine

    GlaxoSmithKline said it would move its experimental vaccine against the respiratory syncytial virus (RSV), a cause of pneumonia in toddlers and the elderly, into the final stage of testing, encouraged by mid-stage trial results. RSV vaccine development has been fraught with setbacks for decades but the pharma industry is gearing up to bring a first inoculation to market over the next few years. GSK said a Phase I/II trial with about 1,000 healthy adults aged 60-80 showed that the vaccine prompted a "robust" increase in antibodies and immune cells one month after injection, indicating a stimulated immune system.